Beam Therapeutics Reports Wider Q3 Net Loss, Lower Revenue
Beam Therapeutics reported a wider net loss and lower revenue in the third quarter.
Story updates
01:43:44 PM UTC
SquawkNews
Beam Therapeutics reported third-quarter 2026 revenue of $307K, down 96.8% from $9.7M a year earlier, and a net loss of $134.4M, or $1.28 per diluted share. The net loss widened from $112.6M, or $1.1 per diluted share, in the prior-year quarter.Financial HighlightsBusiness HighlightsOriginal SEC Fi…
01:44:37 PM UTC
SquawkNews
Beam Therapeutics reported a third-quarter 2026 net loss of $134.4 million, or $1.28 per share, compared with a net loss of $112.6 million a year earlier. Cash, cash equivalents and marketable securities totaled $1.04 billion at September 30, 2026, and the company expects its cash runway to extend…